Prevencio, Inc. announced on 11/12/18 data demonstrating high accuracy for its multiple-protein HART AKITM test. Researchers believe these important findings, presented November 10 at the 2018 American Heart Association (AHA) Scientific Sessions in Chicago, will lead to more accurate prediction of AKI risk. This could alter patient management and reduce the alarming incidence of AKI.
In this study, researchers evaluated the company’s AI-driven HART AKI test on 889 patients undergoing cardiac catheterization in Massachusetts General Hospital’s (MGH) Catheter Sampled Blood Archive in Cardiovascular Disease (CASABLANCA) study. The HART AKI test algorithmically interprets six clinical and protein variables (history of diabetes, blood urea nitrogen to creatinine ratio, C-reactive protein, osteopontin, CD5 antigen-like, and Factor VII). The HART AKI had an impressive negative predictive value of 98% and an overall accuracy measurement of 82% (AUC=0.82).
Principal investigator James L. Januzzi, MD, practicing cardiologist at MGH and Professor of Medicine at Harvard Medical School, said, “AKI following coronary angiographic procedures is associated with significant morbidity and death. A test that accurately predicts risk for AKI is of great value, as it can alter patient management; this might include minimizing dye exposure and increasing pre-procedure hydration. In patients with diabetes or heart failure, where risk for Chronic Kidney Disease (CKD) is higher, a high HART AKI score may lead to delaying elective angiography plans until such comorbidities are better managed. Additionally, we believe HART tests could also play an important role in identifying high risk patients for enrollment in clinical trials, thereby saving time and lowering overall trial costs.”
Cardiac catheterization (also called cardiac cath or coronary angiogram) is an invasive imaging procedure that allows your doctor to evaluate blood flow to your heart. During cardiac catheterization, a thin tube, called a catheter, is inserted in an artery or vein, usually in your groin area, and is threaded through your blood vessels to your heart. Contrast dye is injected for imaging and is the primary cause of AKI.
The number of cardiac catheterization or percutaneous coronary intervention (PCI) cases resulting in AKI rose almost 3‐fold from 2001 to 2011. Prediction and prevention strategies, such as the HART AKI test, are needed to reverse this alarming rise in AKI.
Prevencio is using AI to power CVD related blood tests. Employing this novel approach, the company has produced six blood tests to date that significantly improve diagnoses for a variety of heart and blood vessel-related complications.
These tests are:
1. HART CADTM – obstructive coronary artery disease diagnosis
2. HART CVETM – 1-year risk of heart attack, stroke or cardiac death
3. HART PADTM – peripheral artery disease diagnosis
4. HART ASTM – aortic valve stenosis diagnosis
5. HART AMPTM – risk of amputation
6. HART AKITM – risk of acute kidney injury